LLY

961.82

-2.72%↓

JNJ

241.58

-0.43%↓

ABBV

221.77

-0.26%↓

NVS

154.71

-0.15%↓

AZN

192.41

+0.27%↑

LLY

961.82

-2.72%↓

JNJ

241.58

-0.43%↓

ABBV

221.77

-0.26%↓

NVS

154.71

-0.15%↓

AZN

192.41

+0.27%↑

LLY

961.82

-2.72%↓

JNJ

241.58

-0.43%↓

ABBV

221.77

-0.26%↓

NVS

154.71

-0.15%↓

AZN

192.41

+0.27%↑

LLY

961.82

-2.72%↓

JNJ

241.58

-0.43%↓

ABBV

221.77

-0.26%↓

NVS

154.71

-0.15%↓

AZN

192.41

+0.27%↑

LLY

961.82

-2.72%↓

JNJ

241.58

-0.43%↓

ABBV

221.77

-0.26%↓

NVS

154.71

-0.15%↓

AZN

192.41

+0.27%↑

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

230.15 2.54

Buy Sell

Overview

Share price change

24h

Current

Min

226.16

Max

231.2

Key metrics
By Trading Economics
Income	28M -33M
Sales	32M 245M
Profit margin	-13.56
Employees	1,189
EBITDA	68M 15M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+29.69% upside

Dividends
By Dow Jones
Next Earnings	30 kwi 2026

Market Stats
By TradingEconomics
Market Cap	1.2B 15B
Previous open	227.61
Previous close	230.15

News Sentiment

By Acuity

54%

46%

282 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 mar 2026, 21:37 UTC

Acquisitions, Mergers, Takeovers

Lensar and Alcon Agree to Terminate Merger

16 mar 2026, 19:06 UTC

Major News Events

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16 mar 2026, 17:44 UTC

Acquisitions, Mergers, Takeovers

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16 mar 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 mar 2026, 23:46 UTC

Market Talk

Nikkei May Rise After Oil Prices Decline -- Market Talk

16 mar 2026, 23:37 UTC

Market Talk

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16 mar 2026, 23:05 UTC

Market Talk

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16 mar 2026, 21:56 UTC

Market Talk

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16 mar 2026, 21:41 UTC

Market Talk

Major News Events

Global Equities Roundup: Market Talk

16 mar 2026, 21:41 UTC

Market Talk

Major News Events

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16 mar 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16 mar 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16 mar 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16 mar 2026, 20:57 UTC

Acquisitions, Mergers, Takeovers

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16 mar 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16 mar 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 mar 2026, 20:50 UTC

Market Talk

Major News Events

Energy & Utilities Roundup: Market Talk

16 mar 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 mar 2026, 19:53 UTC

Major News Events

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16 mar 2026, 19:43 UTC

Market Talk

Global Equities Roundup: Market Talk

16 mar 2026, 19:43 UTC

Market Talk

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16 mar 2026, 19:37 UTC

Market Talk

Major News Events

Natural Gas Follows Oil Prices Lower -- Market Talk

16 mar 2026, 19:20 UTC

Major News Events

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16 mar 2026, 19:17 UTC

Market Talk

Major News Events

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16 mar 2026, 19:00 UTC

Market Talk

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16 mar 2026, 18:23 UTC

Market Talk

LME Restarts Trading After Outage -- Market Talk

16 mar 2026, 17:36 UTC

Major News Events

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16 mar 2026, 17:19 UTC

Market Talk

Grains Sink as Investors Steer Toward Equities -- Market Talk

16 mar 2026, 17:14 UTC

Major News Events

Trump Ends News Conference

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

29.69% upside

12 Months Forecast

Average 293.08 USD 29.69%

High 342 USD

Low 255 USD

Based on 13 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

282 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.